NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals - Has The Bull Case Changed?
GSK and Ionis Pharmaceuticals recently reported that their experimental hepatitis B therapy bepirovirsen met primary endpoints in two Phase 3 trials, achieving a statistically significant and clinically meaningful functional cure rate and supporting planned global regulatory filings.
The success of bepirovirsen not only adds a potentially first-in-class hepatitis B treatment to Ionis’s RNA-based portfolio, it also activates up to US$150,000,000 in potential milestones plus tiered royalties...